George M. Eliopoulos, M.D.

Editor

• Professor of Medicine, Harvard Medical School (2001-Present)
• Physician, Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA (1982-Present)

Area of Special Interest

• Antimicrobial Resistance
• Antimicrobial Activity

Professional Recognitions & Appointments

• Former Editor-in-Chief of the American Society for Microbiology’s Antimicrobial Agents and Chemotherapy
• Advisor - Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute
• Fellow - Infectious Diseases Society of America
• Fellow - American College of Physicians

Publication Highlights

Over 160 publications including:

• Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics. Antimicrobial Agents and Chemotherapy – May 2016
• Impact of daptomycin resistance on Staphylococcus aureus virulence. Virulence – 2015
• Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. The Journal of Infectious Diseases – June 2012
• Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One - January 2012

Education

• Harvard University (A.B)
• Harvard Medical School (Medical School)
• Columbia-Presbyterian Medical Center (Residency)
• Massachusetts General Hospital (Fellowship)
• Harvard Medical School (Fellowship Robert C. Moellering, Jr., M.D.)

Disclosures

• Nabriva Therapeutics, 2018
• Melinta Therapeutics, 2018
• Zavante Therapeutics, 2017
• Taxis Pharmaceuticals, 2016